NL-OMON45502撤回不适用
A Phase I, open-label study to investigate the pharmacokinetics of GLPG2451 given as two doses of a capsule formulation in healthy subjects - Pharmacokinetics study of GLPG2451 in healthy subjects
Galapagos SAS0 个研究点目标入组 12 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •- Male subject or female subject of non-childbearing potential between 18-50 years of age, inclusive, on the date of signing the informed consent form (ICF).
- •- Female subjects must be of non-childbearing potential defined as surgically sterile (hysterectomy, bilateral salpingectomy and bilateral oophorectomy), or post-menopausal (at least 12 consecutive months without menstruation, without an alternative medical cause [including hormone replacement therapy]).
- •- Have a body mass index between 18-30 kg/m2, inclusive.
- •- Judged by the investigator to be in good health based upon the results of a medical history, physical examination, vital signs, 12-lead ECG, and clinical safety laboratory tests prior to the initial study drug administration. Clinical safety laboratory test results must be within the laboratory reference ranges, or test results that are outside the reference ranges need to be considered non-clinically significant in the opinion of the investigator. One retest is allowed if deemed appropriate by the investigator.
- •- Discontinuation of all medications (including over-the-counter and/or prescription medication, dietary supplements, nutraceuticals, vitamins and/or herbal supplements) except occasional paracetamol (maximum dose of 2 g/day and maximum of 10 g/2 weeks) at least 2 weeks prior to the first study drug administration.
- •- Able and willing to comply with the prohibitions and restrictions and with the contraceptive requirements (male subjects only), as described
- •in the protocol.
- •- Able and willing to sign the ICF as approved by the Independent Ethics Committee (IEC), prior to any screening evaluations.;Reference is made to the protocol for a complete overview of the inclusion criteria.
排除标准
- •- Known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug as determined by the investigator, such as
- •anaphylaxis requiring hospitalization.
- •- Clinically significant symptoms or illness in the 3 months prior to screening.
- •- Presence or having sequelae of gastrointestinal, liver, kidney or other conditions known to interfere with the absorption, distribution,
- •metabolism, or excretion of drugs.
- •- Evidence of lens opacity on slit lamp examination or similar system.
- •- Significant blood loss (including blood donation [>500 mL]), or a transfusion of any blood product within 12 weeks prior to the first study
- •drug administration.
- •- Treatment with any drug known to have a well-defined potential for toxicity to a major organ in the last 3 months or 5 times the half-life of
- •the drug (whichever is longer) prior to the first study drug administration.
- •- Participation in a drug, drug and device delivery system or combination, or biologic investigational research study within 8 weeks or
- •5 times the half-life of the investigational drug, if the half-life is known (whichever is longer) prior to the first study drug administration.;Reference is made to the protocol for a complete overview of the exclusion criteria.
研究者
相似试验
已完成
1 期
Pharmacokinetics of Miist Nicotine Inhaler in healthy smokersSmoking cessationMental Health - AddictionACTRN12623001317684Miist Therapeutics South Pty Ltd10
已完成
不适用
A Phase I, open-label trial to investigate the pharmacokinetic interaction between TMC125 and two antifungal agents (fluconazole and voriconazole), all at steady-state in healthy subjects.AIDSHIV10021460NL-OMON32571Tibotec Pharmaceuticals Ltd, EastGate Village, Eastgate, Little Island, CO Cork, Ireland, In Nederland vertegenwoordigd door Janssen-Cilag B.V.18
进行中（未招募）
1 期
Research done in healthy human volunteers to Investigate how the MK-8342B (ENG-E2, 125/300 µg/day) Vaginal Ring behaves in and influences the body of female Postmenarcheal Adolescents and Healthy Female Adults.Hormonal contraception and primary dysmenorrhea in woman seeking contraception.MedDRA version: 19.0Level: LLTClassification code 10073728Term: Hormonal contraceptionSystem Organ Class: 100000004865EUCTR2015-005284-16-ATMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
已完成
不适用
A Phase I, Open-Label Study to Investigate the Pharmacodynamics and Pharmacokinetics of Etonogestrel (ENG) and 17*-Estradiol (E2) in Healthy Young Adult Women Following Administration of MK-8342B (ENG-E2, 125/300 *g/day) Vaginal Ring for an Extended Period of Timedysmenorrheahormonal contraception and primary dysmenorrhea in womencontraceptionNL-OMON43028Merck Sharp & Dohme (MSD)20
进行中（未招募）
1 期
A Study to Investigate the Pharmacokinetics (PK) and Safety of Risdiplam in Infants with Spinal Muscular AtrophySpinal Muscular Atrophy (SMA)MedDRA version: 20.1Level: LLTClassification code: 10041583Term: Spinal muscular atrophy unspecified Class: 10010331MedDRA version: 20.1Level: PTClassification code: 10041582Term: Spinal muscular atrophy Class: 100000004850MedDRA version: 20.1Level: LLTClassification code: 10051203Term: Spinal muscular atrophy congenital Class: 10010331CTIS2023-505602-42-00F. Hoffmann-La Roche AG10